GDMC

GDMC, short for Genetic Design and Manufacturing Corporation, represents an ambitious stride in the biopharmaceutical industry, founded in 2021. Positioned at the forefront of next-generation advanced genetic medicines, GDMC operates out of Singapore, focusing on partnerships with early-stage companies and innovative investigators to propel pioneering therapeutic modalities, including gene therapies and nucleic acids.

The company stands out with its robust capabilities in process development and manufacturing, aimed at expediting the journey from clinical trials to market availability—a critical edge in the competitive biopharma landscape. Encouraging a dynamic work environment, GDMC underscores its commitment to diversity and equal opportunities in its rapidly growing team.

Recently, GDMC secured a $21.00M Series A investment on 01 January 2024, from notable investors such as WI Harper Group, SEEDS Capital, NSG Ventures, and Celadon Partners, signalling strong investor confidence and fueling its development trajectory.